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Over recent years biotechnology has been
instrumental in the development of key
medicines such as monoclonal antibodies for
the treatment of cancer and autoimmune
conditions such as rheumatoid arthritis and
psoriasis, human insulin for the treatment of
diabetes, and the cloning of erythropoietin to
stimulate the production of red blood cells in
the treatment of chronic anemia.
In this fast-paced area of medical research,
we feel it is of utmost importance for specialist
and generalist healthcare professionals alike to
have access to the most up to date and relevant
research, including analysis on how this
research translates to treatment strategies in
clinical practice. Each biological therapy has a
highly sensitive and specific mode of action in
relation to particular indications and therapy
areas, and as such it was felt that research in
these areas would be better suited to therapeutic
area-specific journals, where data and
information will gain optimal exposure and
recognition in that particular field to the most
relevant audience.
In accordance with this approach, Biologics in
Therapy will be closing at the end of 2015. The
Adis journal portfolio continues to welcome
content relating to the discovery, development,
and use of biological and biosimilar therapies in
all medical fields, including high-quality
preclinical, clinical (all phases), observational,
real-world, and health outcomes research
around the discovery, development, and use of
such therapies. Studies relating to diagnosis,
pharmacoeconomics, public health, quality of
life, and patient care, management, and
education are also encouraged throughout the
portfolio.
For information on alternative Adis journal
options or any other enquires please contact
advancesintherapy@springer.com.
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